Oxoglaucine mediates Ca 2+ influx and activates autophagy to alleviate osteoarthritis through the TRPV5/calmodulin/CAMK‐II pathway

Gang Zhong,Huiping Long,Fei Chen,Yin Yu
DOI: https://doi.org/10.1111/bph.15466
IF: 7.3
2021-05-05
British Journal of Pharmacology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Stimulation of calcium influx and suppression of autophagy play important roles in the pathogenesis of osteoarthritis (OA). In this study, we use a novel TRPV5 inhibitor ‐ oxoglaucine to attenuate progression of deterioration and pathological changes on OA patient‐derived chondrocytes and OA animal model by activating autophagy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>The inhibition by oxoglaucine on calcium channel was detected <i>in vitro</i>. Analyses were also carried out to investigate the effect of oxoglaucine on OA by detection of anti‐inflammatory response, TRPV5/CAMK‐II/Calmodulin pathway, autophagy and cartilage protection both <i>in vitro</i> and <i>in vivo</i>. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Oxoglaucine suppressed the expression of pro‐inflammatory and apoptosis‐related cytokines, such as TNF‐α, IL‐6, IL‐1β, MMP‐13, CASP‐3, BAX, and prevented matrix degradation in OA chondrocytes. It also successfully blocked Ca<sup>2+</sup> influx, activating autophagy dose‐dependently as evidenced by up‐regulated expression of LC‐3II/I, Beclin‐1, ATG5, ATG7, higher autophagic influx and autophagic vesicles formation. It also decreased the mRNA and protein expression of TRPV5, CAMK‐II and Calmodulin. Conversely, 1, 25‐dihydroxyvitamin D3, as agonists of TRPV5, reversed the oxoglaucine induced calcium influx inhibition and autophagy activation, demonstrating the association of oxoglaucine with TRPV5. Further, oxoglaucine effectively prevented against the apoptosis and matrix degradation of articular cartilage in OA joints of rats, demonstrated by macroscopic evaluation and histological findings. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>Oxoglaucine protects against cartilage damage by blocking TRPV5/CAMK‐II/Calmodulin pathway to inhibit Ca<sup>2+</sup> influx and activate autophagy. Our results indicate that oxoglaucine has potential to become a candidate drug for treatment of OA. </p></section>
pharmacology & pharmacy
What problem does this paper attempt to address?